Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Many Physicians Prescribe Medium/High-Dose Pill: User Education Needed
August 6, 2001
- BUSINESS NEWS IN BRIEF
August 6, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
August 6, 2001
- Yoshitomi to Focus Only on Psychiatric Field
August 6, 2001
- Dr Kawakita Urges Medical Facilities to Improve Quality of Services: Seminar
August 6, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
August 6, 2001
- Kenporen to Cooperate with Nikkeiren, Rengo in Healthcare Reform
August 6, 2001
- CRO Business Expanding Rapidly: Association Report
August 6, 2001
- Chamber Councils Selection System to Be Started in Medical Malpractice Suits
August 6, 2001
- Kasamatsu Meiki, Hokuho Iyaku to Merge on Oct. 1
August 6, 2001
- WORLD NEW IN BRIEF
August 6, 2001
- Int'l Licensing Symposium to Be Held in Tokyo in September
August 6, 2001
- Gap between Boots and Mitsubishi Strategies Seen in Close of 4 Stores
August 6, 2001
- Development of Kissei's Rizaben Discontinued by GSK
August 6, 2001
- Sun Drug-Kawachi Yakuhin Alliance Likely to Be Successful: Security Analyst
August 6, 2001
- 3 Groups to Study How to Improve Supply of Drug Information
August 6, 2001
- BULLETIN
August 6, 2001
- BULLETIN
August 6, 2001
- Council Recommends Abolition of \205 Rule, Review of NHI Pricing Rule
August 6, 2001
- DIAGNOSTIC NEWS IN BRIEF
August 6, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…